Please login to the form below

Not currently logged in
Email:
Password:

Astellas regains bladder drug from GSK

Astellas Pharma US has exercised its right under a co-promotion agreement with GlaxoSmithKline to take back commercial responsibility in the US for overactive bladder treatment Vesicare

Astellas Pharma US has exercised its right under a 2003 co-promotion agreement with GlaxoSmithKline (GSK) to take back full commercial responsibility in the US for its overactive bladder treatment VESIcare (solifenacin succinate).

The companies have been co-promoting Vesicare in the US since the drug was launched in 2005. However, Astellas said it would now take over all promotional activities for the product and that GSK sales reps would no longer promote the drug. The change is expected to take place after a transition period that will end no later than January 2012.

Specific financial terms of the arrangement were not disclosed, but Astellas said it would make "certain payments" to GSK until 2015, when the co-promotion deal had been scheduled to conclude.

"GlaxoSmithKline has been an instrumental partner for Astellas in this successful co-promotion since the company first introduced Vesicare into the marketplace," the company said. "Astellas Pharma US will work with GlaxoSmithKline over the coming months to ensure a smooth and transparent transition."

Vesicare was the first product to be launched by Yamanouchi Pharma America, Japan-based Astellas' independent sales and marketing network in the US. The drug is among Astellas' top-selling products, with annual North American sales of about $431m. However, it is due to lose its patent protection in the US market in 2018.

To help mitigate the effects of generic competition for Vesicare, Astellas is developing a next-generation overactive bladder treatment called mirabegron, which the company filed for marketing approval in Japan in June 2010. The drug has a different mechanism of action than Vesicare and may produce fewer side effects.

17th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics